Home » Amgen completes acquisition of KAI Pharmaceuticals
Amgen completes acquisition of KAI Pharmaceuticals
July 6, 2012
Thousand Oaks, Calif.-based Amgen has completed the acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco.
The acquisition was initially announced April 10, 2012, and includes KAI's lead product candidate KAI-4169—a novel agent being studied initially for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis.
KAI has previously reported compelling phase IIa clinical results for KAI-4169 in this indication. KAI-4169 is administered intravenously at the same time the patient is undergoing dialysis.
Upcoming Events
-
23Apr
-
07May
-
14May